vimarsana.com

Latest Breaking News On - Normane sharpless - Page 7 : vimarsana.com

The Cancer Moonshot: A Midpoint Progress Update

Credit: National Cancer Institute It’s hard to believe that 4 years have passed since the Cancer Moonshot℠ was “launched.” In December 2016, Congress passed the 21st Century Cures Act, which authorized $1.8 billion in funding for the Cancer Moonshot over 7 years. Even though it is only at the midway point in terms of funding, we believe it is well on its way to producing meaningful improvements for people with cancer. Supporters heralded the Cancer Moonshot as “an enormous, once-in-a-lifetime opportunity for the cancer community and our nation to come together around a single disease that touches everyone.”  The architects of the Moonshot articulated three ambitious goals for the Cancer Moonshot: to accelerate scientific discovery in cancer, foster greater collaboration, and improve the sharing of data. 

COVID-19's impact on cancer prevention and control in Africa

 E-Mail When the COVID-19 pandemic reached Africa, the continent was already struggling to deal with another public health crisis - a growing cancer epidemic characterized by more than one million new cancer cases and nearly 700,000 deaths per year. In a Perspective, Beatrice Wiafe Addai and Wilfred Ngwa discuss the significant challenges COVID-19 imposed on cancer prevention and control in Africa and how the efforts to address these challenges highlight key opportunities where greater investment could improve cancer care globally. At the start of the pandemic, many African governments were forced to rapidly divert already limited medical and healthcare resources away from cancer patients to treat those infected with SARS-CoV-2 and slow the spread of COVID-19. According to the authors, many African countries curtailed or cut cancer prevention activities, including awareness education and outreach, early detection screening, and vaccination, gaps that are likely to persist beyond th

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.